Pubblicazioni

  1. Vincenzi F, Ravani A, Pasquini S, Merighi S, Gessi S, Romagnoli R, Baraldi PG, Borea PA, Varani K. “Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety” Neuropharmacol., 2016; 111:283-292. [IF: 5.25].
  2. Varani K, Vincenzi F, Ravani A, Pasquini S, Merighi S, Gessi S, Setti S, Cadossi M, Borea PA, Cadossi R. “Adenosine receptors as a biological pathway for the anti-inflammatory and beneficial effects of low frequency low energy pulsed electromagnetic fields” Mediators Inflamm., 2017; 2017:2740963. [IF: 4.71].
  3. Vincenzi F, Ravani A, Pasquini S, Merighi S, Gessi S, Setti S, Cadossi R, Borea PA, Varani K. “Pulsed electromagnetic field exposure reduces hypoxia and inflammation damage in neuron-like and microglial cells” J. Cell Physiol., 2017; 232(5):1200-1208. [IF: 6.38].
  4. Squarcialupi L, Betti M, Catarzi D, Varano F, Falsini M, Ravani A, Pasquini S, Vincenzi F, Salmaso V, Sturlese M, Varani K, Moro S, Colotta V. “The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles” J Enzyme Inhib. Med. Chem., 2017; 32(1):248-263. [IF: 5.05].
  5. Ravani A, Vincenzi F, Bortoluzzi A, Padovan M, Pasquini S, Gessi S, Merighi S, Borea PA, Govoni M, Varani K. “Role and function of A2A and A3 adenosine receptors in patients with ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis” Int. J. Mol. Sci., 2017; 18(4):pii: E697. [IF: 5.92].
  6. Catarzi D, Varano F, Falsini M, Varani K, Vincenzi F, Pasquini S, Dal Ben D, Colotta V. ”Development of novel pyridazinone-based adenosine receptor ligands” Bioorg. Med. Chem Lett., 2018; 28(9):1484-1489. [IF: 2.82].
  7. Varano F, Catarzi D, Falsini M, Vincenzi F, Pasquini S, Varani K, Colotta V. “Identification of novel thiazolo[5,4-d]pyrimidine derivatives as human A1 and A2A adenosine receptor antagonists/inverse agonists” Bioorg. Med. Chem., 2018; 26(12):3688-3695. [IF: 3.64].
  8. Varano F, Catarzi D, Vincenzi F, Falsini M, Pasquini S, Borea PA, Colotta V, Varani K. “Structure-activity relationship studies and pharmacological characterization of N5-heteroarylalkyl-substituted-2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based derivatives as inverse agonists at human A2A adenosine receptor” Eur. J. Med. Chem., 2018; 155:552-561. [IF: 6.51].
  9. Betti M, Catarzi D, Varano F, Falsini M, Varani K, Vincenzi F, Pasquini S, di Cesare Mannelli L, Ghelardini C, Lucarini E, Dal Ben D, Spinaci A, Bartolucci G, Menicatti M, Colotta V. “Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity” J. Med. Chem., 2019; 62(15):6894-6912. [IF: 7.45].

10.  Catarzi D, Varano F, Varani K, Vincenzi F, Pasquini S, Dal Ben D, Volpini R, Colotta V. "Amino-3,5-dicyanopyridines targeting the adenosine receptors ranging from pan ligands to combined A1/A2B partial agonists” Pharmaceuticals (Basel). 2019; 12(4):159. [IF: 5.86].

11.  Varano F, Catarzi D, Vincenzi F, Pasquini S, Pelletier J, Lopes Rangel Fietto J, Espindola Gelsleichter N, Sarlandie M, Guilbaud A, Sévigny J, Varani K, Colotta V. “Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A2A receptor as potential antitumor agents” Bioorg. Med. Chem., Lett. 2020; 30(9):127067. [IF: 2.82].

12.  Pasquini S, Vincenzi F, Casetta I, Laudisi M, Merighi S, Gessi S, Borea PA, Varani K. "Adenosinergic system involvement in ischemic stroke patients' lymphocytes” Cells, 2020; 9(5):E1072. [IF: 6.60].

13.  Vincenzi F, Pasquini S, Gessi S, Merighi S, Romagnoli R, Borea PA, Varani K.” The detrimental action of adenosine on glutamate-induced cytotoxicity in PC12 cells can be shifted towards a neuroprotective role through A1AR positive allosteric modulation” Cells, 2020; 9(5):E1242. [IF: 6.60].

14.  Varano F, Catarzi D, Vigiani E, Vincenzi F, Pasquini S, Varani K, Colotta V. “Piperazine- and piperidine-containing thiazolo[5,4-d-pyrimidine derivatives as new potent and selective adenosine A2A receptor inverse agonists” Pharmaceuticals (Basel), 2020;13(8):161. [IF: 5.86].

15.  Vincenzi F, Pasquini S, Battistello E, Merighi S, Gessi S, Borea PA, Varani K. “A1 adenosine receptor partial agonists and allosteric modulators: advancing toward the clinic?” Front. Pharmacol., 2020;11:625134. [IF: 5.81].

16.  Vincenzi F, Pasquini S, Borea PA, Varani K. “Targeting adenosine receptors: a potential pharmacological avenue for acute and chronic pain” Int. J. Mol. Sci., 2020; 21(22):8710. [IF: 5.92].

17.  Vincenzi F*, Pasquini S*, Setti S, Salati S, Cadossi R, Borea PA, Varani K. “Pulsed electromagnetic fields stimulate HIF-1α-independent VEGF release in 1321N1 human astrocytes protecting neuron-like SH-SY5Y cells from oxygen-glucose deprivation” Int. J. Mol. Sci., 2020; 21(21):8053. (*, co-first authors) [IF: 5.92].

18.  Varani K, Vincenzi F, Pasquini S, Blo I, Salati S, Cadossi M, De Mattei M. “Pulsed electromagnetic field stimulation in osteogenesis and chondrogenesis: signaling pathways and therapeutic implications” Int. J. Mol. Sci., 2021; 22(2):809. [IF: 5.92].

19.  Merighi S, Poloni TE, Pelloni L, Pasquini S, Varani K, Vincenzi F, Borea PA, Gessi S. “An open question: is the a2a adenosine receptor a novel target for alzheimer's disease treatment?” Front. Pharmacol., 2021; 12:652455. [IF: 5.81].

20.  Pasquini S, Contri C, Borea PA, Vincenzi F, Varani K. “Adenosine and inflammation: here, there and everywhere” Int. J. Mol. Sci., 2021, 22, 7685. [IF: 5.92].